Telomir Pharmaceuticals (NASDAQ:TELO) has been featured in a local ABC exclusive highlighting promising age reversal outcomes in two senior dogs using their novel small molecule, Telomir-1. The compassionate use program, observed by Dr. Michael Roizen, showed remarkable improvements in the dogs' health and vitality. Zeus, a 12-year-old German Shepherd, experienced complete remission of terminal cancer, while Benson, a 12-year-old Newfoundland with severe arthritis, regained mobility.
Erez Aminov, Telomir's new Chairman CEO, emphasized the company's commitment to advancing Telomir-1's research and accelerating its path to market. Dr. Roizen expressed excitement about Telomir-1's potential to promote cell regeneration and reverse aspects of aging by lengthening telomeres. The company aims to progress towards human trials for specific indications.